NEW YORK (GenomeWeb) – The US Food and Drug Administration has approved the PD-L1 (SP142) Assay developed by Roche subsidiary Ventana as a complementary diagnostic for Genentech's PD-L1 inhibitor Tecentriq, which was recently approved to treat lung cancer.

The complementary assay, while not required for the safe and effective use of Tecentriq, can determine patients' PD-L1 expression levels, which in turn "can provide insight into the survival benefit that may be achieved" with treatment, Roche said in a statement today. The test gauges PD-L1 expression in tumor and immune cells.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.